Analysis of Novel Anticoagulants for Atrial Fibrillation – Pharmacokinetics and Pharmacological Considerations.
Loading...
Date
2014-10
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Atrial Fibrillation (AF) is the most common arrhythmia. AF is a major risk factor for stoke.
Warfarin has been available for more than 60 years and until recently it was the only oral
anticoagulant used for the prevention of stroke. Despite the extensive studies and proven
efficacy, its utility is limited by multiple factors. Warfarin interacts with a multitude of drugs
and foods, has a delayed onset of action, has a narrow therapeutic range, requires
routine lab monitoring and exhibits variable responses in patients. The novel agents
dabigatran, rivaroxaban and apixaban have the potential to have some of the limitations
of warfarin. This article will discuss the pharmacokinetic and pharmacological
considerations and different characteristics of the novel anticoagulants when used for the
prevention of AF.
Description
Keywords
Novel anticoagulants, dabigatran, rivaroxaban, apixaban, direct thrombin inhibitor, factor Xa inhibitor
Citation
Colquitt Charlie, Jones Jocelyn D, Jackson Sylvia H. Analysis of Novel Anticoagulants for Atrial Fibrillation – Pharmacokinetics and Pharmacological Considerations. Cardiology and Angiology An International Journal. 2014 Oct-Dec: 2(4): 278-292.